Peapack-Gladstone Financial Corp’s AbbVie ABBV Stock Holding History

Peapack-Gladstone Financial Corp’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$46.1M	Sell	212,011 -3,628	-2%	-$805K	0.59%	43
2025 Q4	$49.3M	Sell	215,639 -2,321	-1%	-$529K	0.62%	41
2025 Q3	$50.5M	Sell	217,960 -4,950	-2%	-$1.01M	0.66%	36
2025 Q2	$41.4M	Buy	222,910 +20,164	+10%	+$3.75M	0.59%	47
2025 Q1	$42.5M	Sell	202,746 -3,620	-2%	-$704K	0.63%	36
2024 Q4	$36.7M	Sell	206,366 -3,097	-1%	-$569K	0.53%	49
2024 Q3	$41.4M	Buy	209,463 +10,697	+5%	+$2M	0.6%	41
2024 Q2	$34.1M	Buy	198,766 +323	+0.2%	+$53.5K	0.52%	48
2024 Q1	$36.1M	Sell	198,443 -689	-0.3%	-$119K	0.57%	48
2023 Q4	$30.9M	Buy	199,132 +1,305	+0.7%	+$190K	0.52%	52
2023 Q3	$29.5M	Sell	197,827 -1,807	-0.9%	-$265K	0.55%	49
2023 Q2	$26.9M	Buy	199,634 +3,851	+2%	+$565K	0.48%	57
2023 Q1	$31.2M	Sell	195,783 -1,349	-0.7%	-$206K	0.59%	42
2022 Q4	$31.9M	Buy	197,132 +4,585	+2%	+$703K	0.63%	43
2022 Q3	$25.8M	Sell	192,547 -24,385	-11%	-$3.5M	0.53%	55
2022 Q2	$33.2M	Sell	216,932 -131	-0.1%	-$20K	0.76%	33
2022 Q1	$35.2M	Buy	217,063 +18,037	+9%	+$2.62M	0.69%	36
2021 Q4	$26.9M	Buy	199,026 +810	+0.4%	+$95.7K	0.51%	57
2021 Q3	$21.4M	Buy	198,216 +16,694	+9%	+$1.91M	0.44%	63
2021 Q2	$20.4M	Buy	181,522 +3,296	+2%	+$371K	0.49%	55
2021 Q1	$19.3M	Buy	178,226 +15,641	+10%	+$1.67M	0.5%	56
2020 Q4	$17.4M	Buy	162,585 +13,827	+9%	+$1.33M	0.52%	54
2020 Q3	$13M	Buy	148,758 +2,579	+2%	+$243K	0.47%	60
2020 Q2	$14.4M	Sell	146,179 -156	-0.1%	-$13.7K	0.57%	52
2020 Q1	$11.1M	Sell	146,335 -3,198	-2%	-$272K	0.53%	60
2019 Q4	$13.2M	Sell	149,533 -1,935	-1%	-$161K	0.53%	61
2019 Q3	$11.5M	Sell	151,468 -4,919	-3%	-$337K	0.49%	65
2019 Q2	$11.4M	Sell	156,387 -1,468	-0.9%	-$115K	0.49%	62
2019 Q1	$12.7M	Buy	157,855 +1,778	+1%	+$145K	0.58%	56
2018 Q4	$14.4M	Buy	156,077 +1,475	+1%	+$130K	0.74%	47
2018 Q3	$14.6M	Sell	154,602 -3,442	-2%	-$326K	0.71%	48
2018 Q2	$14.6M	Buy	158,044 +600	+0.4%	+$58.6K	0.76%	43
2018 Q1	$14.9M	Sell	157,444 -3,573	-2%	-$393K	0.81%	39
2017 Q4	$15.6M	Sell	161,017 -1,418	-0.9%	-$134K	0.84%	39
2017 Q3	$14.4M	Sell	162,435 -8,144	-5%	-$620K	0.83%	40
2017 Q2	$12.4M	Buy	170,579 +2,074	+1%	+$139K	0.74%	49
2017 Q1	$11M	Sell	168,505 -1,911	-1%	-$120K	0.68%	55
2016 Q4	$10.7M	Sell	170,416 -1,319	-0.8%	-$80.5K	0.69%	51
2016 Q3	$10.8M	Buy	171,735 +29	+0%	+$1.88K	0.72%	48
2016 Q2	$10.6M	Buy	171,706 +1,261	+0.7%	+$76.8K	0.73%	48
2016 Q1	$9.74M	Buy	170,445 +15,726	+10%	+$877K	0.68%	53
2015 Q4	$9.17M	Sell	154,719 -4,060	-3%	-$234K	0.64%	52
2015 Q3	$8.64M	Buy	158,779 +4,816	+3%	+$313K	0.65%	49
2015 Q2	$10.3M	Buy	153,963 +3,716	+2%	+$243K	0.72%	46
2015 Q1	$8.8M	Buy	150,247 +5,143	+4%	+$311K	0.61%	52
2014 Q4	$9.5M	Buy	145,104 +192	+0.1%	+$12.1K	0.67%	50
2014 Q3	$8.37M	Sell	144,912 -75	-0.1%	-$4.16K	0.63%	51
2014 Q2	$8.18M	Sell	144,987 -95	-0.1%	-$4.98K	0.61%	51
2014 Q1	$7.46M	Sell	145,082 -3,036	-2%	-$153K	0.59%	52
2013 Q4	$7.82M	Sell	148,118 -2,480	-2%	-$122K	0.63%	47
2013 Q3	$6.74M	Sell	150,598 -12,379	-8%	-$549K	0.59%	52
2013 Q2	$6.74M	Buy	+162,977	New	+$7.13M	0.62%	51

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Peapack-Gladstone Financial Corp's ABBV Position: Q1 2026 in Review

Peapack-Gladstone Financial Corp reduced its AbbVie (ABBV) stake by 1.7% in Q1 2026, selling an estimated $805K and leaving 212,011 shares worth $46.1M. The position accounts for 0.59% of the portfolio, ranked #43.

Peapack-Gladstone Financial Corp first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $50.5M in Q3 2025. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Peapack-Gladstone Financial Corp held 212,011 shares of AbbVie worth $46.1M as of Q1 2026.
Peapack-Gladstone Financial Corp sold 3,628 AbbVie shares in Q1 2026, an estimated $805K.
AbbVie made up 0.59% of Peapack-Gladstone Financial Corp's portfolio in Q1 2026, its #43 holding.
Peapack-Gladstone Financial Corp first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
Peapack-Gladstone Financial Corp's AbbVie position peaked at $50.5M in Q3 2025.
4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Peapack-Gladstone Financial Corp's 13F filing for Q1 2026, filed 15 May 2026.